Cardinal Health, Inc.
Cardinal Health, Inc. CAH Peers
See (CAH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CAH | $154.72 | +0.39% | 36.9B | 24.21 | $6.39 | +1.31% |
| MCK | $712.89 | +0.18% | 89.2B | 27.70 | $25.74 | +0.40% |
| COR | $288.94 | +0.18% | 56B | 33.48 | $8.63 | +0.75% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $70.37 | -0.14% | 8.6B | 21.92 | $3.21 | N/A |
| PBH | $85.09 | +0.55% | 4.2B | 19.83 | $4.29 | N/A |
| PDCO | $31.33 | -0.90% | 2.8B | 20.48 | $1.53 | +1.66% |
| GRDN | $20.65 | -1.29% | 1.3B | -12.99 | -$1.59 | N/A |
| OMI | $8.01 | +5.26% | 613.7M | -1.68 | -$4.76 | N/A |
| WGRX | $1.69 | -2.87% | 121.4M | -2.19 | -$0.77 | N/A |
Stock Comparison
CAH vs MCK Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, MCK has a market cap of 89.2B. Regarding current trading prices, CAH is priced at $154.72, while MCK trades at $712.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas MCK's P/E ratio is 27.70. In terms of profitability, CAH's ROE is -0.50%, compared to MCK's ROE of -1.33%. Regarding short-term risk, CAH is less volatile compared to MCK. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs COR Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, COR has a market cap of 56B. Regarding current trading prices, CAH is priced at $154.72, while COR trades at $288.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas COR's P/E ratio is 33.48. In terms of profitability, CAH's ROE is -0.50%, compared to COR's ROE of +2.41%. Regarding short-term risk, CAH is less volatile compared to COR. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs ABC Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, CAH is priced at $154.72, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas ABC's P/E ratio is 21.92. In terms of profitability, CAH's ROE is -0.50%, compared to ABC's ROE of +2.52%. Regarding short-term risk, CAH is less volatile compared to ABC. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs HSIC Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, HSIC has a market cap of 8.6B. Regarding current trading prices, CAH is priced at $154.72, while HSIC trades at $70.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas HSIC's P/E ratio is 21.92. In terms of profitability, CAH's ROE is -0.50%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, CAH is less volatile compared to HSIC. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs PBH Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, PBH has a market cap of 4.2B. Regarding current trading prices, CAH is priced at $154.72, while PBH trades at $85.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas PBH's P/E ratio is 19.83. In terms of profitability, CAH's ROE is -0.50%, compared to PBH's ROE of +0.12%. Regarding short-term risk, CAH is less volatile compared to PBH. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs PDCO Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, CAH is priced at $154.72, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas PDCO's P/E ratio is 20.48. In terms of profitability, CAH's ROE is -0.50%, compared to PDCO's ROE of +0.14%. Regarding short-term risk, CAH is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.
CAH vs GRDN Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, GRDN has a market cap of 1.3B. Regarding current trading prices, CAH is priced at $154.72, while GRDN trades at $20.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas GRDN's P/E ratio is -12.99. In terms of profitability, CAH's ROE is -0.50%, compared to GRDN's ROE of -0.74%. Regarding short-term risk, CAH is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs OMI Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, OMI has a market cap of 613.7M. Regarding current trading prices, CAH is priced at $154.72, while OMI trades at $8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas OMI's P/E ratio is -1.68. In terms of profitability, CAH's ROE is -0.50%, compared to OMI's ROE of -0.51%. Regarding short-term risk, CAH is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs WGRX Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, WGRX has a market cap of 121.4M. Regarding current trading prices, CAH is priced at $154.72, while WGRX trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas WGRX's P/E ratio is -2.19. In terms of profitability, CAH's ROE is -0.50%, compared to WGRX's ROE of -1.74%. Regarding short-term risk, CAH is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs ZYXI Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, ZYXI has a market cap of 65.9M. Regarding current trading prices, CAH is priced at $154.72, while ZYXI trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas ZYXI's P/E ratio is -9.08. In terms of profitability, CAH's ROE is -0.50%, compared to ZYXI's ROE of -0.24%. Regarding short-term risk, CAH is less volatile compared to ZYXI. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs GEG Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, GEG has a market cap of 60.9M. Regarding current trading prices, CAH is priced at $154.72, while GEG trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas GEG's P/E ratio is -43.60. In terms of profitability, CAH's ROE is -0.50%, compared to GEG's ROE of -0.02%. Regarding short-term risk, CAH is less volatile compared to GEG. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs HX Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, CAH is priced at $154.72, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas HX's P/E ratio is -1.84. In terms of profitability, CAH's ROE is -0.50%, compared to HX's ROE of -0.04%. Regarding short-term risk, CAH is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs RDGT Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, RDGT has a market cap of 5.6M. Regarding current trading prices, CAH is priced at $154.72, while RDGT trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas RDGT's P/E ratio is -0.29. In terms of profitability, CAH's ROE is -0.50%, compared to RDGT's ROE of -0.36%. Regarding short-term risk, CAH is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for CAH.
CAH vs CVET Comparison
CAH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAH stands at 36.9B. In comparison, CVET has a market cap of 0. Regarding current trading prices, CAH is priced at $154.72, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAH currently has a P/E ratio of 24.21, whereas CVET's P/E ratio is -69.97. In terms of profitability, CAH's ROE is -0.50%, compared to CVET's ROE of -0.06%. Regarding short-term risk, CAH is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for CAH.